Eosinophilic pneumonia associated with pirfenidone therapy. Issue 4 (7th July 2016)

• Record Type: Journal Article
• Authors: Gomez, Diana C.; Mehrad, Borna
• Is Part Of: European respiratory journal. Volume 48:Issue 4(2016)
• Page Start: 1240
• Page End: 1242
• Publication Date: 2016-07-07
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00809-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

Pulmonary eosinophilia is a common manifestation of drug-induced lung disease and, at the time of writing, some 170 medications have been implicated in eosinophilic pneumonia [1]. Since the reaction occurs rarely for any given drug, however, establishing a causal relationship is difficult, and relies on reports of temporal relationship and exclusion of alternative causes of eosinophilic lung disease. Pirfenidone is an oral antifibrotic drug that is conditionally recommended as therapy for patients with idiopathic pulmonary fibrosis (IPF), based on the results of three randomised controlled trials [2]. Here, we describe what we believe to be the first report of the association of pirfenidone therapy with eosinophilic pneumonia. Pirfenidone therapy may cause eosinophilic lung disease http://ow.ly/xWyh301icn8